Buy Elahere in India — Price & Availability

What is Elahere used for?

Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (FRα)-directed antibody-drug conjugate. It links a chimeric IgG1 antibody that targets the FRα protein on cancer cells to DM4, a microtubule inhibitor payload, via a cleavable linker. After the antibody binds FRα, the conjugate is taken into the cell and releases DM4, delivering the cytotoxic drug more directly to the tumour.

It is approved for adults with:

• FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

Patient eligibility is confirmed by an approved test for FRα expression. It is a prescription anticancer medicine and must be used under the supervision of a qualified oncologist.

Recommended dosage:

The recommended dose of Elahere is 6 mg/kg of adjusted ideal body weight (AIBW), given as an intravenous infusion once every 3 weeks (a 21-day cycle), continued until disease progression or unacceptable toxicity.

• Elahere is given only as an IV infusion — never as an IV push or bolus.
• Pre-medications are given before each infusion to reduce infusion reactions and nausea, and prophylactic eye care (artificial tears and topical steroid eye drops) is used to lower the risk of eye problems.
• The first infusion is typically given at a slower rate with observation; later infusions may be given faster if well tolerated.
• The dose may be interrupted, reduced, or stopped to manage side effects.

The treating oncologist always determines dosing, the number of cycles, and any modifications.

Boxed warning: Elahere carries a boxed warning for ocular (eye) toxicity, including visual impairment, keratopathy (corneal changes), dry eye, photophobia (light sensitivity), eye pain, and uveitis. Eye examinations (including visual acuity and slit-lamp exams) are done before starting treatment, every other cycle for the first 8 cycles, and as clinically needed. Prophylactic eye drops are used, and treatment may be adjusted based on eye findings.

• Ocular toxicity: report any new or worsening vision changes promptly; do not use contact lenses unless advised by the treating team.
• Pneumonitis (lung inflammation): can be serious; report new or worsening cough, shortness of breath, or fever, as treatment may need to be interrupted or stopped.
• Peripheral neuropathy: numbness, tingling, pain, or weakness in the hands or feet should be reported; the dose may be modified.
• Effects on driving/machinery: blurred vision or neuropathy may affect the ability to drive or operate machinery.
• Embryo-fetal toxicity: Elahere can harm an unborn baby; effective contraception is advised during treatment and for 7 months after the last dose, and breastfeeding is not recommended during and for 1 month after treatment.

Common side effects:
Frequently reported effects include blurred vision and other eye changes (keratopathy, dry eye), fatigue, nausea, diarrhoea, abdominal pain, peripheral neuropathy, musculoskeletal pain, constipation, vomiting, decreased appetite, and changes in certain blood and liver tests (such as increased AST/ALT and decreased blood counts). This is not a complete list — refer to the full prescribing information and your oncologist.

Patients in India can legally access Elahere through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Elahere is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

Documents required to import Elahere:

• A valid prescription from a qualified oncologist
• The patient’s diagnostic reports, including FRα (folate receptor alpha) test results
• Government-issued patient ID proof
• An import permit, where applicable

Because Elahere is not sold on the open market in India, there is no fixed MRP. The Elahere cost in India depends on a few factors at the time of import:

• The number of 100 mg vials required per cycle, which is based on the patient’s adjusted ideal body weight and the every-3-week dosing schedule.
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs.

Get a transparent quote: We provide a written quotation covering Elahere cost, logistics, and delivery timeline once a valid prescription is shared. Request your Elahere quote →

Elahere is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid oncologist’s prescription, in line with applicable regulations.

Indian Pharma Network sources Elahere from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Elahere vials require cold-chain handling: stored upright in a refrigerator at 2 °C–8 °C in the original carton, protected from light, and never frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Elahere can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.